Replies to post #720827 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Of course.

Flip just confirmed that he does not expect any cash payout (forget about significant cash) and a big pharma to PR combo trial deal. Rather he expects a small company like Oncovir to be involved! ;)

It’s logical that there will be a major dilution to fund this trial. What I am now thinking is will there be any conditions attached to UK approval like running another confirmatory trial, which is why LP would want to start a larger combo study with Oncovir in 2025. And this is why share price has been tanking with no real buying interest because major dilution is expected? And another reason for not going on a hiring spree and filing reimbursement evidence.

Watch out for sell the news at UK approval! I thought we would at least get a nice spike at UK approval of somewhere in between 100-200%, but that looks very doubtful if UK approval has some conditions attached to it. We might even sell off who knows!

[dstock07734]

You really need to do your homework before betting against the revolutionary science. You mean those researchers from BPs cannot realize how revolutionary is the technology that NWBO owns. Are you trying to be funny?

[Doc logic]

manibiotech,

The nefarious forces will have either been exposed and the market made fully aware they are being looked closely into or they will be exonerated by the grant of motion to dismiss by then so no need to even mention them at that time as that would just be gloating or whining. The market will put a value, up or down, on the outcome of the judge’s ruling but that pales in comparison to what NWBO presents regarding approval and partnership (financing). That I agree with you 100% and it’s time for management to get er done by the time approval roles around. This might be another White Knight to put pressure on big pharma or big pharma themselves. Merck can put a pretty good whammy on BMY if they have a deal with NWBO and BMY doesn’t if BMY doesn’t get approval for their subcutaneous injection of checkpoint inhibitor in December because it is more lethal than IV method. BMY would be forced into needing to announce a CSF-R1 trial agreement with UCLA or NWBO with any bad news from their December padufa date. Best wishes.